That's the purpose of the estimand framework—to define ahead of time, before you even start randomizing patients, everything that can happen, and then define the methods you will use to attenuate the ...

In this video interview, David Morton, PhD, director of biostatistics at Certara, reflects on the growing role of Bayesian ...

An in-depth thought leadership whitepaper explaining how sponsors can operationalize the FDA’s 2025 guidance on inclusive and representative clinical trial design. It outlines current industry ...

This article explores how adopting a “workflow” mindset anchored in measurable sponsor outcomes meets this challenge, ultimately yielding the lower costs, higher quality, and an architecture ready for ...

In addition to improving payment speed, accuracy, and transparency, modern payment technology is creating new opportunities to further improve the trial experience. For example, AI is being used to ...

Closing the gender gap in data science and tech requires tackling barriers at every stage, from early education through career advancement, while actively challenging the unconscious biases that ...

The Patient Advocate Foundation and the PAN Foundation have announced a strategic merger to create the nation’s most ...

In today’s ACT Brief, we highlight how Bayesian methods are reshaping adaptive trial design, a major eSource partnership is ...

In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...

In today’s ACT Brief, we examine how the Verana Health-COTA merger is evolving real-world data use, the FDA’s new framework ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

At the SCOPE Summit, Tekton Research shares how its physician-led clinical trial network is helping accelerate research in neuroscience and cardiometabolic disease. By pairing pra ...